Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07761117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Study acronym: Elevate-HF
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 1 entry Trial sites expanded: 672 → 679 locations · Eligibility criteria expanded, about 19 words · Secondary endpoints: details revised at 2 of 3 entries Show 3 more changesShow less
    • Trial sites expanded: 672 → 679 locations
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 2 of 3 entries
  2. Recruitment opened Trial sites expanded: 366 → 672 locations · Start date changed from estimate of Aug 28, 2026 to Aug 24, 2026 · Secondary endpoints revised (3)v2 Show 3 more changesShow less
    • Trial sites expanded: 366 → 672 locations
    • Start date changed from estimate of Aug 28, 2026 to Aug 24, 2026
    • Secondary endpoints revised (3)

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Heart Failure
1,871 trials monitored
See 100 trials at risk
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Trial Details
NCT Number NCT07761117
Lead Sponsor AstraZeneca
Conditions Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Enrollment 6,950 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov